Waystar Holding Corp. (WAY)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Waystar nears deal to buy Iodine Software for up to $1.2 billion, WSJ reports
Healthcare software firm Waystar is nearing a deal to buy privately held Iodine Software in a deal worth over $1.2 billion including debt, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Waystar Nears Deal for Iodine Software
The deal would value private-equity backed Iodine Software around $1.2 billion, including debt.
Waystar Holding (WAY) Earnings Expected to Grow: Should You Buy?
Waystar (WAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waystar Q1 Review: Navigating Premium Valuation With A View To Buy
Waystar's Q1 2025 revenue rose 14% YoY, driven by strong AI integration, high client retention, and expanding subscription revenues. Recent insider and private equity share sales may pressure the stock price, creating potential buying opportunities for long-term investors like myself. Waystar's AI-powered, integrated RCM platform is capitalizing on industry shifts and delivering superior net revenue retention and client upselling.
Does Waystar (WAY) Have the Potential to Rally 27.23% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 27.2% in Waystar (WAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Earnings Estimates Moving Higher for Waystar (WAY): Time to Buy?
Waystar (WAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Waystar Holding Corp. (WAY) Q1 2025 Earnings Call Transcript
Waystar Holding Corp. (NASDAQ:WAY ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Sandy Draper – Vice President-Investor Relations Matt Hawkins – Chief Executive Officer Steve Oreskovich – Chief Financial Officer Conference Call Participants Adam Hotchkiss – Goldman Sachs Saket Kalia – Barclays Joanna Zhou – Evercore ISI Brian Peterson – Raymond James Allen Lutz – Bank of America Jailendra Singh – Truist Securities George Hill – Deutsche Bank Ryan Daniels – William Blair Richard Close – Canaccord Genuity Anne Samuel – JPMorgan Operator Good day and thank you for standing by. Welcome to the Waystar First Quarter 2025 Earnings Conference Call.
Waystar's Modest FY25 Outlook Faces Growth Challenges: Goldman Sachs Analyst Weighs In
Goldman Sachs analyst Adam Hotchkiss reiterated the Buy rating on Waystar Holding Corp. WAY, with a price forecast of $52.
Here's Why Waystar (WAY) Is a Great 'Buy the Bottom' Stock Now
Waystar (WAY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Waystar Holding Corp. (WAY) Q4 2024 Earnings Call Transcript
Waystar Holding Corp. (WAY) Q4 2024 Earnings Call Transcript
Analysts Rally Behind Waystar: Predict Robust Growth and Market Share Gains Following Competitor Setback
BofA Securities analyst Allen Lutz initiated coverage on Waystar Holding Corp. WAY with a Buy rating and price forecast of $27.
Waystar: Healthcare Payment Provider Goes Public
Waystar IPO is priced at the midpoint, as shares are trading flat. WAY stock simplifies healthcare payments through its cloud-based software. Valuations are demanding, while profitability is solid, as caution is warranted due to high earnings multiples and potential AI disruption.
